Skip to main content

Advertisement

Table 3 Main clinical characteristics of included articles

From: Subcutaneous immunotherapy with depigmented-polymerized allergen extracts: a systematic review and meta-analysis

No. Year First autor Rhinoconjunctivitis severity (ARIA) Asthma severity (GINA) Mean age (SD or range) PDCO groups of age Patients not included in PP analysis
Active group (%) Placebo group (%)
1 2010 Pfaar Mild to severe Only intermittent 39 (18 to 65) Only adults 14.6 14.9
2 2013 Pfaar Moderate to severe Only intermittent 31 (12.4) Adolescent included 14.5 17.2
3 2012 Pfaar Moderate to severe Only intermittent 33 (11 to 69) Children Included 23.7 25
4 2010 Höiby  Mild to severe Intermittent to mild 33 (7 to 69) Children Included 22.6 30
5 2006 Colás Mild to severe Intermittent to mild 34 (18 to 51) Only adults 5 5
6 2005 Ameal Mild to severe Intermittent to moderate 23 (14 to 48) Adolescent included 9.4 16.1
7 2006 García-Robaina Moderate to severe Intermittent to moderate 24 (9.3) Adolescent included 20 20
8 2005 Álvarez-Cuesta Moderate to severe Intermittent to mild 28 (17 to 58) Adolescent included
  1. ARIA allergic rhinoconjunctivitis and its impact on Asthma, GINA global initiative for Asthma, PDCO European Medicines Agency. Paediatric Committee, PP Per protocol, SD Standard deviation